Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Files An 8-K Regulation FD Disclosure
Item 7.01
| Regulation FD Disclosure. |
On December 19, 2016, at 8:30 a.m. Eastern Time, Brainstorm Cell
Therapeutics Inc. (the Company) will hold a conference call to
provide an update to stockholders to discuss ongoing progress
with NurOwn in the treatment of amyotropic lateral sclerosis
(ALS) and Company plans for 2017. Notice of this conference call
was previously given on December 6, 2016 via press release, a
copy of which is furnished as Exhibit 99.1 to this Form 8-K.
This information shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange
Act, except as shall be expressly set forth by specific reference
in such a filing.
| Item 8.01 | Other Events. |
On December 19, 2016, the Company issued a press release
providing a corporate update and announced its clinical
development objectives for 2017. A copy of the press release is
attached as Exhibit 99.2 to this Current Report on Form 8-K and
is incorporated by reference herein.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit No. |
Description |
|
| 99.1 | Press Release dated December 6, 2016 | |
| 99.2 | Press Release dated December 19, 2016 |
About Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Recent Trading Information
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) closed its last trading session down -0.19 at 2.69 with 322,908 shares trading hands.